Palatin Technologies: Positive Phase 2b Results and Strategic Growth Opportunities Justify Buy Rating
HC Wainwright & Co. Reiterates Buy on Palatin Techs, Maintains $17 Price Target
Palatin Techs Analyst Ratings
Palatin Technologies: Strategic Focus on Obesity and Diversified Pipeline Justifies Buy Rating
Palatin Techs Analyst Ratings
HC Wainwright & Co. Reiterates Buy on Palatin Techs, Maintains $17 Price Target
Palatin Techs Analyst Ratings
HC Wainwright & Co. Reiterates Buy on Palatin Techs, Maintains $17 Price Target
Buy Rating Affirmed: Palatin Technologies' Strong Earnings and Promising Pipeline Signal Growth Opportunities
Positive Buy Rating for Palatin Technologies Based on Promising Obesity and ED Clinical Trials
Palatin Techs Analyst Ratings
HC Wainwright & Co. Reiterates Buy on Palatin Techs, Maintains $17 Price Target
Palatin Techs Analyst Ratings
HC Wainwright & Co. Reiterates Buy on Palatin Techs, Maintains $17 Price Target
Palatin Techs Analyst Ratings
HC Wainwright & Co. Reiterates Buy on Palatin Techs, Maintains $17 Price Target
Analysts Offer Insights on Healthcare Companies: Palatin Technologies (PTN), Prestige Consumer Healthcare (PBH) and CervoMed (CRVO)
Palatin Techs Analyst Ratings
HC Wainwright & Co. : The Palatin Techs (PTN.US) rating was reaffirmed and adjusted from buy to buy, with a target price of $17.00.
Analysts Are Bullish on These Healthcare Stocks: AEON Biopharma (AEON), Palatin Technologies (PTN)
Unlock the Full List